Forte Biosciences Business Summary

Forte Biosciences, Inc. (FBRX) is a clinical-stage biopharmaceutical company that operates as a pre-revenue entity, with its business model centered on the development and potential commercialization of novel therapies for autoimmune and inflammatory diseases. The company’s primary focus is its lead candidate, FB-102, a proprietary anti-CD122 monoclonal antibody targeting indications with high unmet needs, including celiac disease, non-segmental vitiligo, and alopecia areata. Forte currently generates no revenue from product sales, instead funding operations through capital markets and targeting future revenue via licensing, milestone payments, or direct commercialization. In the competitive landscape, Forte positions itself against peers such as Zymeworks, Precigen, and Coherus Biosciences, distinguishing itself through its specialized CD122 antagonist approach within the autoimmune dermatology and gastrointestinal sectors. The leadership team is anchored by Founder, CEO, and Chairman Dr. Paul A. Wagner, Ph.D., whose background includes serving as CFO of Pfenex Inc. and a Portfolio Manager at Allianz Global Investors. The executive suite is further comprised of CFO Antony A. Riley, formerly of Krystal Biotech, and COO Christopher Roenfeldt, who brings experience from Halozyme, Genentech, and Amgen. Clinical development is led by Senior Medical Clinician Dr. Barbara K. Finck, M.D., the former CMO of Coherus BioSciences. Forte’s board includes notable industry figures such as Scott Brun, M.D. (former VP at AbbVie) and David Gryska (former CFO of Incyte and Celgene), with institutional backing from major investors like Fred Alger Management, Federated Hermes, and Orbimed Advisors.